Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4475993 | 0.98 | HTR6 (0.56) | HTR6TAAR1 | |
| SCHEMBL25316518 | 0.89 | HTR6 (0.59) | HTR6TAAR1 | |
| SCHEMBL30439496 | 0.89 | HTR6 (0.59) | HTR6TAAR1 | |
| SCHEMBL171817 | 0.87 | HTR6 (0.58) | HTR6TAAR1 | |
| SCHEMBL30681216 | 0.87 | HTR6 (0.58) | HTR6TAAR1 | |
| SCHEMBL21366390 | 0.87 | HTR6 (0.47) | HTR6TAAR1 | |
| Hydrochloric Acid SCHEMBL7140687 | 0.86 | HTR6 (0.59) | HTR6TAAR1 | |
| SCHEMBL2274164 | 0.81 | PARP1 (0.51) | HTR6TAAR1 | |
| SCHEMBL9904432 | 0.81 | HTR6 (0.49) | HTR6TAAR1 | |
| Benzenethiol SCHEMBL2226315 | 0.79 | HTR6 (0.54) | HTR6TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3596073-B1 | TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS. | ARGONAUT THERAPEUTICS LTD (GB) | 2022-05-11 | — | — | EP | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | claimed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | claimed |
| EP-1019408-B1 | 1,2,3,4-TETRAHYDRO-BENZOFURO[3,2-c]PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2004-06-30 | — | — | EP | claimed |
| US-6156757-A | 1,2,3,4-tetrahydro-benzofuro[3,2-C]pyridine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-12-05 | — | — | US | claimed |
| EP-1019408-A1 | 1,2,3,4-TETRAHYDRO-BENZOFURO 3,2-c]PYRIDINE DERIVATIVES-- | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-19 | — | — | EP | claimed |
| WO-1998045297-A1 | 1,2,3,4-TETRAHYDRO-BENZOFURO[3,2-c]PYRIDINE DERIVATIVES__ | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-15 | — | — | WO | claimed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2023-11-14 | — | — | US | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-05-14 | — | — | US | disclosed |
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | AC IMMUNE SA (CH) | 2020-04-28 | — | — | US | disclosed |
| US-6156757-A | 1,2,3,4-tetrahydro-benzofuro[3,2-C]pyridine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-12-05 | — | — | US | disclosed |
| US-6156757-A | 1,2,3,4-tetrahydro-benzofuro[3,2-C]pyridine derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-12-05 | — | — | US | disclosed |
| EP-1019408-A1 | 1,2,3,4-TETRAHYDRO-BENZOFURO 3,2-c]PYRIDINE DERIVATIVES-- | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-19 | — | — | EP | disclosed |
| EP-1019408-A1 | 1,2,3,4-TETRAHYDRO-BENZOFURO 3,2-c]PYRIDINE DERIVATIVES-- | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998045297-A1 | 1,2,3,4-TETRAHYDRO-BENZOFURO[3,2-c]PYRIDINE DERIVATIVES__ | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-15 | — | — | WO | disclosed |
| WO-1998045297-A1 | 1,2,3,4-TETRAHYDRO-BENZOFURO[3,2-c]PYRIDINE DERIVATIVES__ | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10633383-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | HTR6 2143/4885TAAR1 2296/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HTR6 176/4885TAAR1 125/4885 |
| US-20200148679-A1 | Novel compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, MAP1LC3B | HTR6 2414/4885TAAR1 2056/4885 |
| US-11814378-B2 | Compounds for the treatment, alleviation or prevention of disorders associated with Tau aggregates | MAPT, MAP1LC3A, TUBB3 | HTR6 2143/4885TAAR1 2296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.